TrialCurrent oncology (Toronto, Ont.)2021

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care.

Adam J N Raymakers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.